SynCore Biotechnology

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
SynCore is an innovative drug development company focused on dermatology, ophthalmology and oncology. Co-founded by a locally established pharma, the Sinphar Group and the National Health Research Institute (Taiwan), its mission is to pioneer technology that will overcome barriers in unmet medical needs. With a comprehensive pipeline of drugs and medical devices in various stages from pre-clinical to marketed. Currently, the lead asset, SB05 EndoTAG-1 for pancreatic cancer second-line treatment is undergoing global phase III clinical trial in Asia, US and Europe. Interim analysis is expected to be released in Q3 this year, showing data on clinical efficacy and safety profile. SynCore is actively looking for commercialization partners in US and Europe, as well as co-development partners in China and Japan.
Ticker:
4192
Exchange:
Taipei Exchange
Company Type:
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
EndoTAG-1
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
BD Specialist
SynCore Biotechnology